Comments
Wall Street’s broader market averages closed mixed on Friday as market participants digested the U.S. government shutdown for the third day.
For the week, the Dow, S&P 500, and Nasdaq Composite advanced by 1.1%, 1.08%, and 1.32%, respectively.
The S&P 500 Health Care
Quick Insights
TrumpRx offers Pfizer drugs at discounts up to 85%, potentially increasing sales volume but reducing per-unit revenues, especially for drugs like Xeljanz. Increased accessibility could bolster Pfizer’s market share if more drugmakers join the program.
Morgan Stanley forecasts slowing US prescription growth for Novo’s GLP-1 drugs, market share and price pressure in future, and only modest growth overall, citing increased competition from generics and rival products like Eli Lilly’s Mounjaro.
Genmab’s $8B acquisition of Merus will add Petosemtamab, a lead asset with two FDA breakthrough designations, expanding Genmab’s pipeline, with expectations of meaningful EBITDA growth by 2029 and no impact on current full-year outlook.
Recommended For You
More Trending News
About XLV ETF
SymbolLast Price% Chg
1D
5D
1M
6M
1Y
5Y
10Y
Expense Ratio
Div Frequency
Div Rate
Yield
Assets (AUM)
Related Stocks
SymbolLast Price% ChgXLV–The Health Care Select Sector SPDR® Fund ETF
Trending Analysis
Trending News